• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

    3.515 +0.115 (+3.38%)
    Streaming Delayed Price Updated: 10:57 AM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 231,186
    Open 3.500
    Bid (Size) 3.520 (2,000)
    Ask (Size) 3.530 (1,300)
    Prev. Close 3.400
    Today's Range 3.480 - 3.580
    52wk Range 3.115 - 11.29
    Shares Outstanding 68,196,526
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
    From Niagen Bioscience, Inc
    Via Business Wire

    Performance

    YTD
    -43.8%
    -43.8%
    1 Month
    +0.4%
    +0.4%
    3 Month
    -28.7%
    -28.7%
    6 Month
    -42.3%
    -42.3%
    1 Year
    -63.5%
    -63.5%

    More News

    Read More
    Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance ↗
    Via Chartmill
    Topics Earnings
    Niagen Bioscience Inc (NASDAQ:NAGE) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗
    Via Chartmill
    News headline image
    Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
    From Niagen Bioscience, Inc.
    Via Business Wire
    News headline image
    Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Announces Participation in Upcoming Investor Conferences
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen (NAGE) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
    From Niagen Bioscience, Inc
    Via Business Wire
    Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS)
    Via AB Newswire
    News headline image
    Niagen Bioscience Increases Share Repurchase Program to $20 Million
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Present at the 38th Annual ROTH Conference
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
    From Niagen Bioscience, Inc
    Via Business Wire

    Frequently Asked Questions

    Is Niagen Bioscience, Inc. - Common Stock publicly traded?
    Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.
    What exchange does Niagen Bioscience, Inc. - Common Stock trade on?
    Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?
    The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market
    What is the current price of Niagen Bioscience, Inc. - Common Stock?
    The current price of Niagen Bioscience, Inc. - Common Stock is 3.515
    When was Niagen Bioscience, Inc. - Common Stock last traded?
    The last trade of Niagen Bioscience, Inc. - Common Stock was at 08/03/26 10:57 AM ET
    What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?
    The market capitalization of Niagen Bioscience, Inc. - Common Stock is 239.71M
    How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?
    Niagen Bioscience, Inc. - Common Stock has 240M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.